Brain volume loss takes place at a faster rate in the first five years of multiple sclerosis than later in disease course, researchers report in a study that calls for scientists to “reconsider” — for this and related reasons — proposals to use volume loss as a measure of treatment efficacy in MS patients.
The study, “Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis,” was published in the journal JAMA Neurology.
Achieving no evidence of disease activity (NEDA-3), as defined by three clinical and imaging criteria, has been proposed as an MS treatment goal. But, although a valuable approach to capturing the inflammatory burden of the disease, scientists think that NEDA-3 might underestimate that the extent of nerve fiber injury and its contribution to disability.
Measuring brain volume is one approach being considered as a possible way of marking nerve fiber injury in MS.
Research has shown that brain